title: Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer.
abstract: BACKGROUND
  In elderly patients treated with chemotherapy for advanced non-small cell lung cancer (NSCLC), frequently an adequate dose intensity (DI) is difficult to be delivered. We therefore performed in this population a study to assess the delivered DI and its impact on clinical outcome.
  
  
  METHODS
  Inclusion criteria were: age equal or greater than 70 years; cytological or histological diagnosis of NSCLC; stage IIIB or IV; no previous chemotherapy for advanced disease. Total relative dose intensity (RDI) was taken into account for the analysis. An RDI less than 80% was considered as suboptimal for tumor shrinkage. A survival comparison between subgroups (more or less than 80% RDI) was done.
  
  
  RESULTS
  107 patients were eligible for the analysis. Mean age was 74.3 years. PS was 0-1 in 92.5% of subjects. Mean number of comorbidities was 1.86. The most frequently chemotherapy regimens used were single agent vinorelbine and single agent gemcitabine. Overall mean RDI was 68%; 36% of patients received a RDI>80% of the originally planned one. The objective response rate (RR) was 55.2% and 33.3% respectively for patients receiving more or less than 80% of the RDI (p<0.01); a significant difference in overall survival between these two groups (p<0.0001) was also recorded. Baseline hemoglobin and body mass index (BMI) were the variables that significantly influenced the delivered RDI.
  
  
  CONCLUSIONS
  These data suggest that in elderly patients treated with chemotherapy for advanced NSCLC an adequate dose intensity has a significant positive impact on both response rate and overall survival.
authors.affiliation: Medical Oncology Unit, S. Paolo Hospital, 20142 Milan, Italy. andrea.luciani@ao-sanpaolo.it
authors.forename: A
authors.initials: A
authors.lastname: Luciani
authors.forename: C
authors.initials: C
authors.lastname: Bertuzzi
authors.forename: G
authors.initials: G
authors.lastname: Ascione
authors.forename: E
authors.initials: E
authors.lastname: Di Gennaro
authors.forename: S
authors.initials: S
authors.lastname: Bozzoni
authors.forename: S
authors.initials: S
authors.lastname: Zonato
authors.forename: D
authors.initials: D
authors.lastname: Ferrari
authors.forename: P
authors.initials: P
authors.lastname: Foa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents